Wire · opportunities
Tecentriq Plus Chemotherapy Wins Approval for Stage III dMMR Colon Cancer After Halving ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 October 2026 · Fusion42 review
The U.S. FDA approved atezolizumab (Tecentriq) combined with chemotherapy for stage III mismatch repair-deficient (dMMR) colon cancer, based on a trial showing it halves the risk of recurrence or death compared to chemotherapy alone. This is the first adjuvant immunotherapy approved for this cancer subtype, with a treatment course lasting about one year.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 9 Oct 2026 and 11 Oct 2026.
◆ ◆ The Wire takeaway
Immunotherapy combined with chemotherapy now sets a new standard for stage III dMMR colon cancer post-surgery care. You need to integrate dMMR tumor testing into your route to market to reach patients eligible for this treatment.
◆ Coverage
3 sources · first reported 9 Oct 2026 · latest 11 Oct 2026
◆ Related on Wire
◆ Topics